Turning Pennies into dollars: (OTC: HSXI), (OTCBB: RMDX), (NASDAQ: OSIR), (NASDAQ: EXAC), (PINKSHEETS: WTVN).
Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559
For more info: http://hsxi.realpennies.com
HealthSonix, Inc. (OTC: HSXI) (February 27, 2008)) announced earlier yesterday that the multi-faceted marketing program for ZingiberRx Joint and Muscle Cream launched earlier this month is hitting stride and exceeding company expectations. The program consisted of launching the website, sampling, direct to consumer sales, test markets in retail stores, and advertising on Google search engines.
"Yesterday alone, we had over 5,300 visits to our website and received over 5,000 requests for samples," said Dieter D. Doederlein, Vice President of Corporate Development for HealthSonix. "This is significant because early evidence suggests that we have a high conversion rate from sample to purchase, and we continue to get positive feedback from users of all ages." "In addition to the direct to consumer marketing efforts, we have been test marketing the product in regional drug stores and have now progressed to Vendor status with one of the largest national drug store chains in Canada. ZingiberRx is actually the number one selling topical pain reliever in many of the early test locations and we have the full support and participation of the pharmacists when it comes to explaining the product and its benefits," added Doederlein.
"The response to this new pain relieving cream, the first of its kind with ginger, is just short of amazing. It is really rewarding to witness the instant acceptance of ZingiberRx for the relief of pain and inflammation." ZingiberRx joint and muscle cream is fast acting, non-staining, fast absorbing, and deep penetrating. Unlike most over-the-counter topical ointments, ZingiberRx is not a counter-irritant and does not create a hot or a cold sensation when applied.
Medical research studies into the medicinal properties of various plants in the ginger (Zingiberaceae) family have isolated the Zingiber cassumunar species for its anti-inflammatory, anti-allergic and pain relieving properties.
About HealthSonix, Inc.
HealthSonix, Inc. (OTC: HSXI) (FWB: H7S) is a publicly traded research oriented medical technology company that develops and markets medical devices and healthcare products for institutional and consumer use. The company's patent pending medical devices deliver sound pressure waves to the human body for relief of pain and other musculoskeletal conditions. The focus is on arthritis, athletic injuries and conditions where acute or chronic pain is the cardinal symptom. More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.
For more info: http://rmdx.realpennies.com
Criminal offender management and public safety solutions through GPS tracking & monitoring company SecureAlert, a subsidiary of RemoteMDx, Inc. (OTCBB: RMDX)(February 27, 2008) announced earlier yesterday the hiring of John L. Hastings III to the position of Chief Sales & Marketing Officer.
Hastings brings 23 years of progressive general management, consultative sales, business and product/services development, field sales; business-to-business (B2B) and business-to-consumer (B2C) brand management, product marketing; strategic planning, CRM/loyalty marketing, product and services development; global business intelligence; information management and advanced analytics experience in 30 countries with Nestle/Stouffer's, Kraft/General Foods, Nissan Motor Acceptance Corp., NCR/Teredata, Unisys Corp. and VNU/ACNielsen.
Hastings holds an MBA from Pepperdine University, Malibu, CA with a concentration in international marketing, Pacific Rim -- Australasian focus. He spent eight years with VNU/ACNielsen, a $4.5B+ global research, media and publications company headquartered in New York, where he last served as Senior Vice President and General Manager of VNU MI Global Business Intelligence. Most recently, Hastings has been the interim President & CEO of Klever Marketing, Inc. of Salt Lake City, where he has overseen the company's recent-term financial clean-up and business transformation.
Utah-based SecureAlert has added to its executive team in recent months, preparing for expanded deployment within the global criminal management marketplace with an enhanced portfolio of offender management solutions. The cornerstone of each solution is the enhanced TrackerPAL, a single unit, tamper-proof ankle bracelet which features two- and three-way voice communication, GPS monitoring and a high decibel alarm. SecureAlert's products and services solutions are sold to federal, state and local jurisdictions that need real-time tracking solutions for bonded defendants and/or released criminals who require monitoring.
In December, SecureAlert upgraded its monitoring centers by hiring two new industry experts. In addition, the company teamed with Spectrum Design and Solid Design to develop TrackerPAL, which premiered internally this past week.
About SecureAlert
SecureAlert offers law enforcement a unique combination of 24-hour monitoring; tracking and response to geo-zone violations; two- and three-way voice communication; and application-specific software, all packaged in one compact, tamper-resistant device with a 95 decibel alarm. This equipment, in addition to real-time monitoring and training, is offered as a turnkey solution by SecureAlert. Once SecureAlert's monitoring center has been directed to establish parameters of movement by offenders or known predators, any breach in pre-established rules triggers an alarm. At any time of day or night, professionally trained SecureAlert agents can communicate in real-time with an offender through the equipment's built-in communication capability and can contact the appropriate authority. To learn more about SecureAlert, visit www.securealert.com.
About RemoteMDx
RemoteMDx has in excess of 200 employees with a centralized monitoring center located in Sandy, Utah. It has proprietary technologies and offers offender management solution to the criminal justice system including: offender pay programs that require the offenders to pay for their monitoring saving millions of dollars to governmental agencies, drug and alcohol monitoring, real-time monitoring offenders combined with job service programs. RemoteMDx through all of its subsidiaries currently manages in excess of 13,000 offenders and is looking to grow this number through its TrackerPAL HouseArrest solution.
For more info: http://osir.realpennies.com
Osiris Therapeutics, Inc. (NASDAQ: OSIR)(February 27, 2008), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas, announced earlier today the addition Dr. Jeffry Lawrence, M.D. as Executive Medical Director and Dr. Jesus Soriano M.D., Ph.D. as Senior Director of Business Development.
"As our company grows, we will continue to strengthen and broaden our team of dedicated professionals," said C. Randal Mills, Ph.D., President and Chief Executive Officer. "Drs. Lawrence and Soriano not only bring a wealth of knowledge and experience relevant to our mission, but also a passion for pioneering cellular therapies. We welcome them onto our team of tremendously talented individuals who share their vision." Jeffry Lawrence, M.D. serves as the company's Executive Medical Director providing medical leadership to the Company's clinical development programs. Before joining Osiris, Dr. Lawrence was Vice President for Medical Affairs at BD Biosciences. Dr. Lawrence started his career in the pharmaceutical industry at Eli Lilly and Company, where he held leadership positions in clinical research. Prior to joining industry, Dr. Lawrence was Director of Hematology and Hematopathology and Associate Professor of Pathology at Case Western Reserve University and was Assistant Professor of Pathology and Director of Hematology at Virginia Commonwealth University. Dr. Lawrence is board certified in Clinical and Anatomical Pathology and Hematology.
Jesus Soriano, M.D., Ph.D., MBA, serves as the company's Senior Director of Business Development. Prior to joining Osiris, Dr. Soriano served for five years with ATCC, holding leadership positions as Vice President of Intellectual Property, Licensing and International Business Development, Vice President of Licensing, Contacts and Compliance, and Director of Licensing and Business Development. Dr. Soriano also served as Associate Director for Program Management and Business Development at EntreMed, Inc. Prior to joining EntreMed, Dr. Soriano was Assistant Professor at the University of Geneva Medical School, Switzerland and also practiced as a family physician.
About Osiris Therapeutics
Osiris Therapeutics, Inc. is a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas. Osiris currently markets and sells Osteocel for regenerating bone in orthopedic indications. Prochymal is being evaluated in Phase III clinical trials for three indications, including acute and steroid refractory Graft versus Host Disease and also Crohn's disease, and is the only stem cell therapeutic currently designated by FDA as both an Orphan Drug and Fast Track product. Osiris has also partnered with Genzyme Corporation to develop Prochymal as a medical countermeasure to nuclear terrorism and other radiological emergencies. Prochymal is also being developed for the repair of heart tissue following a heart attack and for the protection of pancreatic islet cells in patients with type 1 diabetes. The Company's pipeline of internally developed biologic drug candidates under evaluation also includes Chondrogen for arthritis in the knee. Osiris is a fully integrated company, having developed capabilities in research, development, manufacturing, marketing and distribution of stem cell products. Osiris has developed an extensive intellectual property portfolio to protect the company's technology in the United States and a number of foreign countries including 47 U.S. and 253 foreign patents owned or licensed. More information can be found on the company's website, www.Osiris.com. (OSIR-G)
For more info: http://exac.realpennies.com
Exactech, Inc. (NASDAQ: EXAC)(February 27, 2008), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced earlier today the opening of a wholly-owned distribution subsidiary in Japan and the planned acquisition of a distribution subsidiary in France. Japan and France are two of the largest orthopaedic device markets outside the United States.
Exactech said it will acquire the stock and assets of France Medica SAS, a Strasbourg-based importer and distributor of orthopaedic products and surgical supplies. The total purchase price is projected to be 6.8 million to 7.1 million euros. Exactech expects France Medica's full year 2008 revenues will be approximately 8.0 million euros. The purchase price for France Medica involves 5.4 million euros to be paid upon closing and 1.4 million to 1.7 million euros in earn-out payments based on the performance of France Medica over the next two years. Exactech expects the transaction to be neutral to earnings in 2008 and accretive in 2009. The closing is expected to be completed in the second quarter of 2008.
Exactech also said it has finalized arrangements to create a direct distribution operation in Japan, where it previously sold its products through a distributor. The direct operation sales and logistics subsidiary based in Tokyo enables Exactech to directly control its Japanese marketing and distribution operations. The venture will be headed by Kunio Watanabe, a seasoned orthopaedic marketing executive who has more than 14 years of experience distributing medical products in Japan for U.S. and European companies.
President David Petty said, "France Medica has been a valuable and key strategic partner for a number of years. In addition to distributing our Optetrak knee system, France Medica also provides hips, shoulders, trauma products and instrumentation sets for clinics and hospitals throughout France. We believe we can better serve our French customers by establishing a direct operation in this important market. France Medica currently employs approximately 25 distribution and sales professionals and we are delighted that key members of France Medica's existing management team will stay on as part of the new Exactech subsidiary.
"We have been selling products in Japan through a distributor agreement for over a decade. This new arrangement will allow for continuation of this important relationship while also creating an opportunity for Exactech to expand its market presence in Japan with a new team of seasoned orthopaedic sales professionals in the direct operation. We are enthusiastic about expanding our global presence in the orthopaedic market." More details on Exactech's international expansion will be discussed on the company's 2007 earnings conference call on February 29, 2008 at 11:00 a.m. Eastern time. Exactech will release its fourth-quarter and 2007 year-end earnings on Thursday, February 28, after the market closes.
About Exactech Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech's orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States and Australia, in addition to more than 25 countries in Europe, Asia and Latin America. Additional information about Exactech, Inc. can be found at http://www.exac.com. Copies of Exactech's press releases, SEC filings, current price quotes and other valuable information for investors may be found at http://www.exac.com and http://www.hawkassociates.com.
For more info: http://wtvn.realpennies.com
Wi-Fi TV Inc. (PINKSHEETS: WTVN)(February 27, 2008) earlier today pointed to new research by IDC, the premier global provider of market intelligence, as another compelling reason why Wi-Fi TV's Social Internet TV (www.Wi-FiTV.com) is the perfect product for a new generation.
"Reading the IDC research indicates that young people have migrated from traditional TV to the Internet. Wi-Fi TV's combination of live TV, live chat, and an increasing array throughout 2008 of interactive social communication via the Internet, places Wi-Fi TV with the right platform to reach millions of consumers world wide," said Alex Kanakaris, Chairman and Founder, Wi-Fi TV.
"The new generation of TV is interactive and Internet delivered and that is what Wi-Fi TV is all about. Our strategic plan is to continue rolling out new and exclusive Wi-Fi TV stations and to continue the enhancements to Wi-FiTV.com design and technology so that we have the right arsenal to move up the ranks among global web sites," Mr. Kanakaris added.
"As the new features are rolled out, we will focus our efforts on continuing to raise our number of registered users and sales while also expanding our appeal throughout the United States, China and Europe," Mr. Kanakaris concluded.
According to an IDC press announcement on Feb. 19, 2008, "If you have an Internet connection, chances are you are spending much more time surfing the Web than watching TV. A new IDC study of consumer online behavior found that the Internet is the medium on which online users spend the most time (32.7 hours/week). This is equivalent to almost half of the total time spent each week using all media (70.6 hours), almost twice as much time as spent watching television (16.4 hours), and more than eight times as much time as spent reading newspapers and magazines (3.9 hours)." "The time spent using the Internet will continue to increase at the expense of television and, to a lesser extent, print media," said Karsten Weide, program director, Digital Media and Entertainment at IDC. The data also show that consumers tend to use the media they grew up with. The older the respondents, the more they consume TV, newspapers, and magazines; the younger they are, the more the Internet displaces usage of traditional media. The types of devices employed to access the Internet will continue to diversify, and Internet usage will become more mobile. In addition to desktops, laptops, and mobile phones, a new category of "web gadgets" such as the Amazon Kindle, the Nokia N800, and the Apple iPod touch will use Wi-Fi (connectivity) to access the Internet.
The IDC study, "U.S. Consumer Online Behavior Survey Results 2007 - Part One: Wireline Usage," outlines the results for wireline (i. e., non-mobile) Internet usage from the 2007 U.S. Online Consumer Behavior Survey, which was designed to provide a comprehensive overview of U.S. consumers' online activities. Results are based on a sample of 992 U.S. residents 15 years of age or older who frequently use the Internet, including quotas by gender, age group, ethnicity, region, and income.
IDC (www.idc.com) is the premier global provider of market intelligence, advisory services, and events for the information technology, telecommunications, and consumer technology markets. IDC is a subsidiary of IDG, the world's leading technology media, research, and events company, with 2006 revenues of $2.84 billion.
ABOUT WI-FI TV
Wi-Fi TV is a pioneer of TV on the Internet. Wi-Fi TV Inc. has long touted the coming convergence of TV and the Internet, and provided the first online movie in December 1995.
Wi-Fi TV Inc. provides Social Internet TV, a new generation TV delivery platform that has a geographic sphere out-distancing any traditional cable or over-the-air TV broadcaster.
The Wi-Fi TV website (www.Wi-FiTV.com) is the only place on the Internet where you can watch hundreds of TV stations and chat with others watching the same program in a live chat box directly under the viewing screen, and get breaking news for each country and category listed, and download a free dialer and make phone calls and host live video parties all on one website.
Read our full disclaimer at: http://www.realpennies.com/start.html
Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html
Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html
Sponsored by: http://www.isthemarketopen.com
RealPennies .
Telephone: 1-800-940-6559
Matt /at/ realpennies.com
